Navigation Links
Non-Randomized, Multi-Center US Clinical Trial of the GORE ACUSEAL Vascular Graft Presented at VEITHsymposium in New York
Date:11/19/2013

NEW YORK, Nov. 19, 2013 /PRNewswire-iReach/ -- Principal investigator, Dr. Marc Glickman, chief of Vascular Services for Sentara Healthcare, (Norfolk, VA) announced today at the 40th Annual VEITHsymposium held at the Hilton New York Midtown, 1335 Avenue of the Americas (New York, NY), the results of early cannulation of the GORE ACUSEAL vascular graft for vascular access.  Glickman emphasized that the vascular graft design expands treatment options for earlier removal or possible avoidance of a central venous catheter (a major source of infection for hemodialysis patients). 

Glickman reported, "Early cannulation is made possible by the unique tri-layer design of the GORE ACUSEAL Vascular Graft, featuring a low-bleed elastomeric middle membrane between inner and outer layers of expanded polytetrafluoroethylene (ePTFE). This middle membrane hinders suture line and cannulation needle bleeding and may reduce the risk of seroma formation and pseudoaneurysm. The design is kink resistant and flexible at curves while allowing for precise suturing and anastomotic tailoring."                                             

The recently completed prospective, non-randomized, multi-center US clinical trial (138 subjects) demonstrated that the six-month cumulative patency of the GORE ACUSEAL Vascular Graft is comparable to that of other arteriovenous grafts with 84 percent patency compared to 75 percent patency in the historical control.  The results showed that within 28 days of graft implantation, 75.6 percent of the implanted GORE ACUSEAL Vascular Grafts had been successfully cannulated three consecutive times allowing for the potential for the central venous catheter to be removed."

"With early cannulation, physicians can reduce the number of days patients use tunneled catheters for dialysis, which in turn will reduce the morbidity and mortality for these patients," said Glickman.  "The results of our trial demonstrate that the GORE ACUSEAL Vascular Graft does allow for early cannulation within 72 hours of implantation without the risk of cannulation-related complications such as infection and without reducing the patency of the graft." concluded Glickman. The FDA cleared the graft in April 2013.    

About VEITHsymposium: Now in its fourth decade, VEITHsymposium provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features over 750 rapid-fire presentations from world-renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. To register to attend the VEITHsymposium, please visit www.VEITHpress.org or contact Pauline T. Mayer at 631.979.3780 or email.

Media Contact: Pauline Mayer, PTM Healthcare Marketing, Inc., 631-979-3780, ptm@ptmhcm.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE VEITHsymposium
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
2. EarlySense System Implementation Shown to Reduce Falls, Decrease Transfers to Hospitals and Increase the Quality of Care for Elderly in Multi-Center Nursing Home Study
3. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
4. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
5. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
6. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
7. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
8. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
9. New Clinical Endocrinology Guidelines Support Lp-PLA2 Measurement For Risk Assessment of Coronary Artery Disease
10. First Patient Treated in U.S. Clinical Study of Cohera Medicals TissuGlu® Surgical Adhesive
11. Michael J. Fox Foundation-Funded Study Identifies Best Dyskinesia Clinical Rating Scale
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create ... it streamlines the reporting process and provides a familiar interface that does not ...
(Date:4/28/2017)... ... ... sleep affects much more than energy – it also has mental and physical benefits. According ... reaction time, which can increase the risk of having a car accident. , This ... NSF to help you sleep better and feel better:, , Turn ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly ... offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and ... These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... exposed to more adverse experiences than children in the general population. That’s because ... abuse, neglect or other family challenges. While no fault of their own, youth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
Breaking Medicine News(10 mins):